Kenneth W Mahaffey
Overview
Explore the profile of Kenneth W Mahaffey including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
605
Citations
28003
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Judge D, Alexander K, Cappelli F, Fontana M, Garcia-Pavia P, Gibbs S, et al.
J Am Coll Cardiol
. 2025 Mar;
85(10):1003-1014.
PMID: 40074465
Background: Transthyretin amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed chronic disease associated with progressive heart failure that results in impaired quality of life, repeated hospitalizations, and premature death. Acoramidis is a...
2.
Gibson C, Bahit M, Mehran R, Mehta S, Lamee R, Goto S, et al.
Am Heart J
. 2025 Feb;
285:21-28.
PMID: 39986336
Background: Despite current antiplatelet therapy, patients remain at risk of recurrent ischemic events after acute coronary syndromes (ACS), which may reflect persistently elevated thrombin generation. Factor XIa inhibition reduces thrombin...
3.
Neuen B, Catanese B, Chang A, Heise M, Tricoci P, Eckardt K, et al.
J Am Soc Nephrol
. 2025 Feb;
PMID: 39908111
No abstract available.
4.
Chatur S, Vaduganathan M, Fletcher R, Perkovic V, Heerspink H, Arnott C, et al.
Eur J Heart Fail
. 2025 Jan;
PMID: 39844714
Aims: The sodium-glucose cotransporter 2 inhibitor canagliflozin reduces the risk of heart failure (HF) hospitalization or cardiovascular death and chronic kidney disease (CKD) progression among patients with type 2 diabetes...
5.
Duran J, Shrader P, Hong C, Haddad F, Santana E, Cauwenberghs N, et al.
Circ Cardiovasc Imaging
. 2025 Jan;
18(2):e017380.
PMID: 39801490
Background: Patients with abnormal (positive) exercise electrocardiography, but normal stress echocardiography (+ECG/-Echo), have an increased risk of adverse cardiovascular events compared with patients with a normal (negative) ECG and a...
6.
Tucker A, Nguyen M, Kottilil K, Kwee L, Daubert M, Pagidipati N, et al.
medRxiv
. 2025 Jan;
PMID: 39763547
Coronary artery disease (CAD) and peripheral artery disease (PAD) are common and dangerous conditions that are both driven by atherosclerosis. Despite sharing many major risk factors, their disease pathophysiology is...
7.
Jason M, Marzec L, Piccini J, Shrader P, Pieper K, Blanco R, et al.
Int J Cardiol
. 2024 Dec;
421():132912.
PMID: 39708904
Background: Decisions about stroke prevention strategies in atrial fibrillation (AF) typically balance thromboembolism reduction against increased bleeding from oral anticoagulation therapy (OAC). When determining eligibility for OAC, guidelines recommend calculation...
8.
Feng K, Short S, Saeb S, Carroll M, Olivier C, Simard E, et al.
J Med Internet Res
. 2024 Dec;
26():e60493.
PMID: 39705694
Background: Though widely used, resting heart rate (RHR), as measured by a wearable device, has not been previously evaluated in a large cohort against a variety of important baseline characteristics....
9.
Jain S, Sarraju A, Shah N, Schulman K, Ashley E, Harrington R, et al.
J Am Coll Cardiol
. 2024 Dec;
85(4):378-380.
PMID: 39641738
No abstract available.
10.
Badve S, Bilal A, Lee M, Sattar N, Gerstein H, Ruff C, et al.
Lancet Diabetes Endocrinol
. 2024 Nov;
13(1):15-28.
PMID: 39608381
Background: GLP-1 receptor agonists reduce the risk of major adverse cardiovascular events (MACE) and can also have kidney benefits. However, whether GLP-1 receptor agonists improve clinically important kidney outcomes remains...